425 related articles for article (PubMed ID: 26925503)
1. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
[TBL] [Abstract][Full Text] [Related]
2. Novel Solid Lipid Nanocarrier of Glibenclamide: A Factorial Design Approach with Response Surface Methodology.
Pandey S; Patel P; Gupta A
Curr Pharm Des; 2018; 24(16):1811-1820. PubMed ID: 29788881
[TBL] [Abstract][Full Text] [Related]
3. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
4. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
5. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
6. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
[TBL] [Abstract][Full Text] [Related]
7. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
9. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
10. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake.
Luo Y; Teng Z; Li Y; Wang Q
Carbohydr Polym; 2015 May; 122():221-9. PubMed ID: 25817662
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
12. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.
Lingling G; Yuan Z; Weigen L
Drug Dev Ind Pharm; 2016 Aug; 42(8):1325-33. PubMed ID: 26821124
[TBL] [Abstract][Full Text] [Related]
13. Self-reporter shikonin-Act-loaded solid lipid nanoparticle: formulation, physicochemical characterization and geno/cytotoxicity evaluation.
Eskandani M; Nazemiyeh H
Eur J Pharm Sci; 2014 Aug; 59():49-57. PubMed ID: 24768857
[TBL] [Abstract][Full Text] [Related]
14. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery.
Kumar BS; Saraswathi R; Kumar KV; Jha SK; Venkates DP; Dhanaraj SA
Drug Deliv; 2014 May; 21(3):173-84. PubMed ID: 24102185
[TBL] [Abstract][Full Text] [Related]
16. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.
Van Speybroeck M; Williams HD; Nguyen TH; Anby MU; Porter CJ; Augustijns P
Mol Pharm; 2012 Sep; 9(9):2750-60. PubMed ID: 22870936
[TBL] [Abstract][Full Text] [Related]
17. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
Chen CC; Tsai TH; Huang ZR; Fang JY
Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
[TBL] [Abstract][Full Text] [Related]
19. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
20. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
